Is EFOT or JNJ a better dividend investment in 2026?

EFOT currently yields 2000000.00% with a 5% 5-year dividend growth rate. JNJ yields 2.14% with 5.8% growth. The better choice depends on your goal: EFOT offers higher current income.

What is the dividend yield difference between EFOT and JNJ?

EFOT has a forward dividend yield of 2000000.00% ($2.00/share annually). JNJ yields 2.14% ($5.20/share annually). The yield gap is 1999997.86 percentage points.

Home › Compare › EFOT vs JNJ

EFOT vs JNJ: Dividend Comparison 2026

EFOT yields 2000000.00% · JNJ yields 2.14%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 EFOT wins by $4.879226400974806e+39M in total portfolio value

INVESTMENT

TIME HORIZON10 years

EFOT

● Live price

2000000.00%

Share price

$0.00

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$4.879226400974806e+39M

Annual income

$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00

Full EFOT calculator →

JNJ

Johnson & Johnson

● Live price

2.14%

Share price

$242.49

Annual div

$5.20

5Y div CAGR

28%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$30.5K

Annual income

$4,749.88

Full JNJ calculator →

Portfolio growth — EFOT vs JNJ

📍 EFOT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	EFOT	JNJ
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, EFOT + JNJ cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

EFOT pays

JNJ pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EFOT

Annual income on $10K today (after 15% tax)

$170,000,000.00/yr

After 10yr DRIP, annual income (after tax)

$4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/yr

JNJ

Annual income on $10K today (after 15% tax)

$182.28/yr

After 10yr DRIP, annual income (after tax)

$4,037.40/yr

At 15% tax rate, EFOT beats the other by $4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EFOT + JNJ for your $10,000?

EFOT: 50%JNJ: 50%

100% JNJ50/50100% EFOT

Portfolio after 10yr

$2.439613200487403e+39M

Annual income

$2,439,373,269,665,485,000,000,000,000,000,000,000,000,000,000.00/yr

Blended yield

99.99%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

EFOT

No analyst data

JNJ

Analyst Ratings

Buy

Hold

Sell

Consensus: Buy

Price Target

$228.73

-5.7% upside vs current

Range: $190.00 — $265.00

Altman Z

5.2

Piotroski

4/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EFOT buys

JNJ buys

No recent congressional trades found for EFOT or JNJ in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricEFOTJNJ

Forward yield	2000000.00% ✓	2.14%
Annual dividend / share	$2.00	$5.20 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	28% ✓
Portfolio after 10y	$4.879226400974806e+39M	$30.5K ✓
Annual income after 10y	$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00 ✓	$4,749.88
Total dividends collected	$4.879195005460081e+39M	$15.6K ✓
Payment frequency	quarterly	quarterly
Sector	Stock	Healthcare

Year-by-year: EFOT vs JNJ ($10,000, DRIP)

Year	EFOT Portfolio	EFOT Income/yr	JNJ Portfolio	JNJ Income/yr	Gap
1← crossover	$200,010,700	$200,000,000.00	$10,594	$274.49	+$200.00M → EFOT
2	$3,738,731,768,458	$3,738,517,757,009.35	$11,294	$360.69	+$3738731.76M → EFOT
3	$65,315,062,866,930,490	$65,311,062,423,938,240.00	$12,133	$476.91	+$65315062866.92M → EFOT
4	$1,066,400,830,062,625,000,000	$1,066,330,942,945,357,500,000.00	$13,156	$635.42	+$1066400830062625.00M → EFOT
5	$16,272,182,796,453,826,000,000,000	$16,271,041,747,565,660,000,000,000.00	$14,432	$854.61	+$16272182796453826560.00M → EFOT
6	$232,054,240,113,661,900,000,000,000,000	$232,036,828,878,069,680,000,000,000,000.00	$16,056	$1,162.76	+$2.3205424011366188e+23M → EFOT
7	$3,092,799,066,104,688,500,000,000,000,000,000	$3,092,550,768,067,767,400,000,000,000,000,000.00	$18,175	$1,604.53	+$3.0927990661046884e+27M → EFOT
8	$38,524,105,697,352,694,000,000,000,000,000,000,000	$38,520,796,402,351,967,000,000,000,000,000,000,000.00	$21,009	$2,252.68	+$3.8524105697352695e+31M → EFOT
9	$448,468,826,014,798,700,000,000,000,000,000,000,000,000	$448,427,605,221,702,600,000,000,000,000,000,000,000,000.00	$24,911	$3,229.73	+$4.484688260147987e+35M → EFOT
10	$4,879,226,400,974,806,000,000,000,000,000,000,000,000,000,000	$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00	$30,458	$4,749.88	+$4.879226400974806e+39M → EFOT

EFOT vs JNJ: Complete Analysis 2026

EFOT — Stock

eFotoXpress, Inc. engages in the development and sale of software utility products for compressing large images. Its products include eFotoXpress-Standard Version, a software utility that compresses large images to be sent by email primarily for the retail market; eFotoXpress-Premium Version, a lossless compression software for the enterprise market; eFotoXpress-Medical for medical applications; and PASS, which provides a solution to medical radiology field. The company was incorporated in 1996. It was formerly known as American Multiplexer Corporation and changed its name to eFotoXpress, Inc. in 2005. The company is based in Fremont, California.

Full EFOT Calculator →

JNJ — Healthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →

📬

Get this EFOT vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EFOT vs SCHD EFOT vs JEPI EFOT vs O EFOT vs KO EFOT vs MAIN EFOT vs ABBV EFOT vs MRK EFOT vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.